Analyst
Citi
Equibles does not estimate personal net worth.
Joseph Eric is recorded as Analyst at Citi. Joseph Eric has spoken on 5 earnings calls and 3 other investor events across 7 companies, most recently for BridgeBio Oncology Therapeutics, Inc. on September 10, 2026. Those appearances were for Cytokinetics Inc (CYTK), BridgeBio Oncology Therapeutics, Inc. (BBOT), Biomarin Pharmaceutical Inc (BMRN), Ascendis Pharma A/S (ASND), Ptc Therapeutics, Inc. (PTCT) and 2 other companies. The companies whose calls Joseph Eric spoke on are classified in the Healthcare and Technology sectors.
“Citi's back-to-school biopharma conference. I'm Eric Joseph, Senior Biotech Analyst with the firm. And our next fireside discussion is with BBOT, Bridge Bio-Oncology.”
“Well, welcome to day two of Citi's Back to School Biopharma Conference. I'm Eric Joseph, Senior Biotech Analyst with the firm, and this session is with Biomarin, and I'm happy to be joined by Chief R&D Officer Greg Freeberg and Chief Commercial Officer Kristen Hubbards.”
“One again to Citi's back to school biopharma conference. I'm Eric Joseph, a senior biotech analyst with Citi. And our session this afternoon is with cytokinetics.”
“As far as your named patient programs or your early access programs, can you elaborate a little bit on which markets you're active in, whether eligibility might be determined by treatment status of a patient, and just generally how we should think about whether named patient programs could be meaningful contributors…”
“I just wanted to actually follow up on this point about HCT, or sorry, REM certified HCTs, given the growth that you saw this past quarter.”
Citi
Analyst
Transcript header (unverified)
CYTK
Biotechnology · Healthcare
ASND
Biotechnology · Healthcare
PTC
Software - Application · Technology
